GlassScriptPhysician profile
Michele C Paden
NPI 1043613128
$8,107.07
in general payments reported to CMS, 2019-2025
64 companies · $1,302 in 2025
The $1,302 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $197 · 2022: $1,894 · 2023: $2,862 · 2024: $1,853 · 2025: $1,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,660 · Education: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,659.52 |
| Education | $356.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $544.22 | 2022-2025 | |
| Daiichi Sankyo INC. | $470.88 | 2022-2025 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $435.43 | 2022-2025 | Rybrevant, Erleada, Darzalex |
| Astrazeneca Pharmaceuticals LP | $409.20 | 2022-2025 | Imfinzi, Lynparza, Tagrisso |
| Incyte Corporation | $386.69 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Merck Sharp & Dohme LLC | $344.74 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $343.07 | 2022-2025 | |
| Celgene Corporation | $327.84 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Seagen INC. | $317.55 | 2022-2023 | Adcetris, Tukysa |
| Novartis Pharmaceuticals Corporation | $250.02 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $236.66 | 2022-2025 | Fruzaqla, Ninlaro, Iclusig |
| Gilead Sciences, INC. | $234.01 | 2022-2025 | Trodelvy |
| Lilly USA, LLC | $214.24 | 2022-2025 | Jaypirca, Retevmo, Verzenio |
| Amgen INC. | $192.40 | 2022-2023 | Xgeva, Nplate, Vectibix |
| Astellas Pharma US INC | $173.98 | 2022-2023 | Padcev |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $135.92 | 2022-2025 | |
| Array Biopharma INC | $130.25 | 2022-2024 | Mektovi, Braftovi, Xalkori |
| Tersera Therapeutics LLC | $128.89 | 2022-2025 | Zoladex |
| Glaxosmithkline, LLC. | $125.74 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Regeneron Healthcare Solutions, INC. | $120.40 | 2022-2025 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $118.73 | 2022-2024 | Onivyde, Somatuline Depot |
| Pharmacosmos Therapeutics INC. | $118.18 | 2022-2025 | Monoferric |
| Sumitomo Pharma America, INC. | $112.91 | 2024 | Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $109.30 | 2022-2024 | |
| Springworks Therapeutics, INC. | $109.01 | 2024-2025 | Ogsiveo |
| Dova Pharmaceuticals | $108.63 | 2021 | |
| Kyowa Kirin, INC. | $98.47 | 2022-2025 | Poteligeo |
| E.R. Squibb & Sons, L.L.C. | $87.49 | 2022-2025 | Opdivo |
| Genzyme Corporation | $87.05 | 2022-2024 | |
| Exelixis INC. | $83.29 | 2024-2025 | Cabometyx |
| Stemline Therapeutics INC. | $83.20 | 2023 | Orserdu |
| Sobi, INC | $80.83 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $79.41 | 2022-2024 | Ultomiris |
| Progenics Pharmaceuticals, INC. | $76.82 | 2023-2025 | Pylarify |
| Eisai INC. | $74.71 | 2023 | |
| Puma Biotechnology, INC. | $73.71 | 2022-2024 | |
| Rigel Pharmaceuticals, INC. | $72.19 | 2023-2024 | Rezlidhia, Tavalisse |
| Genentech USA, INC. | $69.60 | 2022-2024 | Tecentriq, Rozlytrek, Alecensa |
| Organon LLC | $67.72 | 2022-2023 | Ontruzant |
| Pharmacyclics LLC, An Abbvie Company | $61.99 | 2023 | Imbruvica |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.36 | 2022-2023 | Gilotrif |
| Agios Pharmaceuticals, INC. | $60.28 | 2022-2025 | Pyrukynd |
| Genmab U.S., INC. | $58.04 | 2024 | Epkinly, Tivdak |
| Kite Pharma, INC. | $55.05 | 2025 | Yescarta |
| Coherus Oncology, INC. | $51.28 | 2024-2025 | Loqtorzi |
| Mirati Therapeutics, INC. | $45.49 | 2023 | Krazati |
| Servier Pharmaceuticals LLC | $42.99 | 2024-2025 | |
| Beigene USA, INC. | $40.06 | 2023-2025 | Brukinsa, Tevimbra |
| Emd Serono, INC. | $34.62 | 2022-2023 | Tepmetko |
| Jazz Pharmaceuticals INC. | $34.05 | 2022 | |
| Alnylam Pharmaceuticals INC. | $33.47 | 2022-2023 | Givlaari |
| Verity Pharmaceuticals INC. | $29.74 | 2022-2023 | Trelstar |
| Karyopharm Therapeutics INC. | $26.85 | 2022 | |
| Adaptive Biotechnologies Corporation | $26.47 | 2023 | Clonoseq |
| Beone Medicines USA, INC. | $26.42 | 2025 | Tevimbra |
| Abbott Laboratories | $25.60 | 2022 | |
| Cti Biopharma Corp. | $23.02 | 2023 | Vonjo |
| Recordati_rare_diseases_inc. | $22.05 | 2023 | Sylvant |
| Sun Pharmaceutical Industries INC. | $21.15 | 2025 | |
| Chiesi USA, INC. | $19.87 | 2023 | Ferriprox |
| Global Blood Therapeutics, INC. | $19.69 | 2022 | |
| Aadi Bioscience, INC. | $19.30 | 2023 | Fyarro |
| Immunocore Limited | $17.90 | 2024 | Kimmtrak |
| Amag Pharmaceuticals, INC. | $16.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Paden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.